Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 303
Filter
1.
Neuropsychobiology ; 63(3): 169-76, 2011.
Article in English | MEDLINE | ID: mdl-21228609

ABSTRACT

BACKGROUND: Depressive disorder after myocardial infarction (MI) is associated with increased cardiac morbidity and mortality. Immune activity such as inflammation might be implicated as an underlying mechanism. The purpose of this study is to investigate whether the response to an antidepressant in post-MI depression is associated with changes of inflammatory markers in serum. METHODS: In a double-blind placebo-controlled study with mirtazapine 30 mg/day (50 patients), the antidepressive effect was related to immune activation parameters. The cytokines interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), the soluble cytokine receptors sIL-6R, sTNF-R1 and sTNF-R2, and the inflammation-sensitive plasma proteins C-reactive protein and neopterin were assessed. RESULTS: Subgroup analyses revealed a highly significant correlation of pronounced sTNF-R1 increase with a decrease in depressive symptoms in antidepressant responders. CONCLUSION: Significant effects on inflammation accompany the therapeutic efficacy of mirtazapine in contrast to the therapeutic efficacy of placebo and the nontherapeutic efficacy of mirtazapine.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depression/drug therapy , Depression/immunology , Mianserin/analogs & derivatives , Myocardial Infarction/complications , Myocardial Infarction/immunology , Receptors, Tumor Necrosis Factor, Type I/drug effects , Adult , Aged , Antidepressive Agents, Tricyclic/pharmacology , Depression/blood , Depression/complications , Female , Humans , Inflammation Mediators/blood , Male , Mianserin/pharmacology , Mianserin/therapeutic use , Middle Aged , Mirtazapine , Myocardial Infarction/blood , Myocardial Infarction/drug therapy , Receptors, Tumor Necrosis Factor, Type I/blood
2.
Prog Neuropsychopharmacol Biol Psychiatry ; 33(1): 49-52, 2009 Feb 01.
Article in English | MEDLINE | ID: mdl-18955102

ABSTRACT

BACKGROUND: The decrease of maternal docosahexaenoic (DHA) status during pregnancy has been associated with postpartum depression, especially in women with a low intake of DHA. Since the DHA intake in the Netherlands is low, we investigated whether supplementation of low doses of DHA or DHA plus arachidonic acid (AA) during pregnancy and lactation could prevent depressive symptoms and sleep disturbances in this period. METHODS: Women were supplemented daily with placebo, DHA (220 mg) or DHA+AA (220 mg each) from week 16 of pregnancy till three months postpartum. Fatty acid analyses were performed in the available plasma samples at 16 and 36 weeks of pregnancy. Depressive symptoms were measured in weeks 16 and 36 of pregnancy and six weeks postpartum using EPDS and within one week postpartum using a blues questionnaire. RESULTS: 119 women completed the study. The average frequency of fish intake was low, 0.94 times per week, and did not differ between the groups. The supplementation groups did not differ in mean EPDS scores or changes in EPDS scores, nor in incidence or severity of postpartum blues. Red blood cell DHA, AA and DHA/AA ratio did not correlate with EPDS or blues scores. Indices of sleep quality did not differ between the groups. CONCLUSION: Supplementation of 220 mg/day DHA or DHA+AA (220 mg/day each) does not prevent peri-partum depressive symptoms, in a population based sample with low background DHA intake. TRIAL REGISTRATION: ISRCTN Register nr. ISRCTN58176213.


Subject(s)
Arachidonic Acid/administration & dosage , Depression, Postpartum/prevention & control , Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Adult , Arachidonic Acid/blood , Docosahexaenoic Acids/blood , Female , Humans , Placebos , Pregnancy , Sleep/drug effects
3.
Prog Neuropsychopharmacol Biol Psychiatry ; 32(5): 1298-301, 2008 Jul 01.
Article in English | MEDLINE | ID: mdl-18502552

ABSTRACT

OBJECTIVE: Assessment of the temporal interrelationship of neuropsychiatric parameters requires technologies allowing frequent biological measurements. We propose glucocorticoid receptor (GR) function of lymphocytes to assess the temporal relationship between glucocorticoid resistance and the course of major depressive disorder. METHOD: Dexamethasone suppression of lymphocyte proliferation was in vitro assessed via 5-bromo-2' deoxyuridine (BrdU) incorporation in DNA. Optimal conditions were determined using blood of healthy volunteers. Thereafter the relation between depression severity (Hamilton Depression Rating Scale, HDRS, scores), lymphocyte proliferation and morning cortisol levels in blood was studied in thirteen depressed patients, mostly with a history of treatment resistance. RESULTS: Recovery from depression was not directly associated with changes in lymphocyte glucocorticoid resistance. However, a negative correlation was observed between HDRS and BrdU incorporation and a positive correlation between morning cortisol and BrdU incorporation. No significant correlation was found between cortisol and HDRS. Regression analyses showed that HDRS was related to both suppression of BrdU incorporation (beta -0.508, p<0.001) and cortisol levels (beta 0.364, p=0.001) in a highly significant model (F2,60=14,244, p<0.001) Except for one case, such relation could not be found within patients. CONCLUSION: Our preliminary results suggest a mutual relation between lymphocyte GR function, morning cortisol levels and MDD symptom severity. A direct relation between glucocorticoids resistance and recovery may not exist, but glucocorticoid resistance might attenuate or prevent recovery. It is clear that additional studies using larger and more homogenous groups of MDD patients are required to support our findings.


Subject(s)
Depression/pathology , Lymphocytes/physiology , Receptors, Glucocorticoid/physiology , Bromodeoxyuridine/metabolism , Cell Count , Cell Proliferation/drug effects , Dexamethasone/pharmacology , Dose-Response Relationship, Drug , Female , Glucocorticoids/pharmacology , Humans , Lymphocyte Activation , Lymphocytes/drug effects , Male , Middle Aged , Psychiatric Status Rating Scales , Regression Analysis
4.
Anal Bioanal Chem ; 389(6): 2029-33, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17909761

ABSTRACT

This report describes a versatile and robust microreactor for bioactive proteins physically immobilized on a polyether sulfone filter. The potential of the reactor is illustrated with glucose oxidase immobilized on a filter with a cut-off value of 30 kDa. A flow-injection system was used to deliver the reactants and the device was linked on-line to an electrochemical detector. The microreactor was used for on-line preparation of apoglucose oxidase in strong acid and its subsequent reactivation with flavin adenine dinucleotide. In addition we describe a miniaturized version of the microreactor used to assess several characteristics of femtomole to attomole amounts of glucose oxidase. A low negative potential over the electrodes was used when ferrocene was the mediator in combination with horseradish peroxidase, ensuring the absence of oxidation of electro-active compounds in biological fluids. A low backpressure at very low flow rates is an advantage, which increases the sensitivity. A variety of further applications of the microreactor are suggested.


Subject(s)
Biosensing Techniques/methods , Enzymes, Immobilized , Glucose Oxidase/analysis , Micropore Filters , Polymers/chemistry , Sulfones/chemistry , Electrochemistry , Electrodes , Ferrous Compounds/chemistry , Flavin-Adenine Dinucleotide/chemistry , Flow Injection Analysis , Glucose Oxidase/metabolism , Horseradish Peroxidase/chemistry , Kinetics , Membranes, Artificial , Metallocenes , Molecular Weight , Oxidation-Reduction , Sensitivity and Specificity
5.
Prog Neuropsychopharmacol Biol Psychiatry ; 31(7): 1347-55, 2007 Oct 01.
Article in English | MEDLINE | ID: mdl-17630064

ABSTRACT

The development of effective and safe drugs for a growing Alzheimer disease population is an increasing need at present. Both experimental and clinical evidence support a beneficial effect of proline-rich polypeptides in a number of neurodegenerative diseases, including Alzheimer disease. Experimental data have shown that proline-rich polypeptides isolated from bovine neurohypophisis possess neuroprotective and neuromodulatory properties in mice with aluminum neurotoxicosis or neuronal damage caused by venoms and toxins. Proline-rich polypeptides from ovine colostrums, so called Colostrinin, have been shown to produce cognitive improvement in an experimental model and in patients with Alzheimer disease. However, the precise mechanism underlying the neuroprotective action of proline-rich polypeptides is not very well established. Moreover, studies pointing at a neuroprotective effect of proline-rich polypeptides from bovine neurohypophisis in humans have not been reported thus far. The authors conclude that more detailed information on the mode of action of proline-rich polypeptides is needed as well as confirmation of their efficacy in broad clinical trials before this approach can really show its potential in the treatment of neurodegenerative disorders.


Subject(s)
Alzheimer Disease/drug therapy , Neurodegenerative Diseases/drug therapy , Peptides/therapeutic use , Proline/therapeutic use , Animals , Caspases/metabolism , Clinical Trials as Topic , Cognition/drug effects , Crush Syndrome/drug therapy , Humans , Hypothalamus/metabolism , Immunity/drug effects , Intercellular Signaling Peptides and Proteins/metabolism , Neurotoxicity Syndromes/drug therapy , Oxidative Stress/drug effects , Peptides/chemistry , Peptides/metabolism , Pituitary Gland/metabolism , Proline/chemistry
6.
Mol Psychiatry ; 12(5): 483-90, 2007 May.
Article in English | MEDLINE | ID: mdl-17453062

ABSTRACT

Highly prevalent stress-related disorders such as major depression (MD) are characterised by a dysregulation of the neuroendocrine system. Although heritability for these disorders is high, the role of genes in the underlying pathophysiology is poorly understood. Here, we show that polymorphic variations in genes coding for serotonin transporter (5-HTT), catechol-O-methyl transferase (COMT) and monoamine oxidase A (MAOA) as well as sex differences influence the regulation of hypothalamic-pituitary-adrenal (HPA)-axis response to acute psychological and endocrine challenges. In our sample, the effects of COMT on the release of adrenocorticotrophin hormone (ACTH) depend on the presence of the low-expression MAOA variant in the same individual. By including individuals varying in their degree of susceptibility to MD, we showed evidence of interactions between 5-HTT and MD susceptibility in baseline cortisol, and between MAOA and MD susceptibility in baseline ACTH measures, indicating a role for these genotypes in stable-state endocrine regulation. Collectively, these results indicate that the simultaneous investigation of multiple monoaminergic genes in interaction with gender have to be measured to understand the endocrine regulation of stress. These findings point towards a genetic susceptibility to stress-related disorders.


Subject(s)
Catechol O-Methyltransferase/genetics , Depressive Disorder, Major/genetics , Monoamine Oxidase/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Stress, Psychological/genetics , Adolescent , Adrenocorticotropic Hormone/metabolism , Adult , Catechol O-Methyltransferase/metabolism , Chi-Square Distribution , Depressive Disorder, Major/metabolism , Epistasis, Genetic , Female , Gene Expression Regulation , Genetic Predisposition to Disease , Humans , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Male , Monoamine Oxidase/metabolism , Pituitary-Adrenal System/metabolism , Reference Values , Serotonin Plasma Membrane Transport Proteins/metabolism , Sex Factors , Stress, Psychological/metabolism
8.
Article in English | MEDLINE | ID: mdl-16384692

ABSTRACT

We assessed essential fatty acid (EFA) and B-vitamin status, together with their determinants, in 61 patients with schizophrenia and established whether those with poor status responded biochemically to the appropriate dietary supplements. As a group, the patients had high erythrocyte saturated fatty acids (FAs), monounsaturated FA and low polyunsaturated FA of the omega3 and omega6 series. Patients reporting not to take vitamin supplements had low vitamin B12 and high homocysteine. Homocysteine variance proved best explained by folate in both the total group and male patients, and by vitamins B12 and B6 in females. Alcohol consumption and duration of illness are risk factors for low polyunsaturated FA status (< P2.5 of reference range), while male gender and absence of fish consumption predict hyperhomocysteinemia (> P97.5 of reference range). Two patients exhibited biochemical EFA deficiency and seven showed biochemical signs of omega3/docosahexaenoic acid (DHA) marginality. Four patients exhibited moderate hyperhomocysteinemia with plasma values ranging from 57.5 to 74.8 micromol/L. None of the five patients with either moderate hyperhomocysteinemia, biochemical EFA deficiency, or both, was predicted by their clinicians to have poor diets. That diet was nevertheless at the basis of these abnormalities became confirmed after supplementing 4 of them with B vitamins and with soybean and fish oils. We conclude that a subgroup of patients with schizophrenia has biochemical EFA deficiency, omega3/DHA marginality, moderate hyperhomocysteinemia, or combinations. Correction seems indicated in view of the possible relation of poor EFA and B-vitamin status with some of their psychiatric symptoms, but notably to reduce their high risk of cardiovascular disease.


Subject(s)
Dietary Supplements , Fatty Acids, Essential/administration & dosage , Schizophrenia/diet therapy , Vitamin B 12/blood , Vitamin B 6/blood , Vitamin B Complex/therapeutic use , Vitamin B Deficiency/diet therapy , Adolescent , Adult , Cross-Sectional Studies , Erythrocytes/chemistry , Erythrocytes/metabolism , Fatty Acids/analysis , Fatty Acids, Essential/deficiency , Fatty Acids, Essential/metabolism , Female , Fish Oils/administration & dosage , Homocysteine/blood , Humans , Male , Middle Aged , Nutritional Status , Sex Factors , Soybean Oil/administration & dosage , Vitamin B 12/therapeutic use , Vitamin B 6/therapeutic use , Vitamin B Deficiency/blood , Vitamin B Deficiency/diagnosis
9.
Auton Neurosci ; 124(1-2): 1-8, 2006 Jan 30.
Article in English | MEDLINE | ID: mdl-16338174

ABSTRACT

In addition to its well-recognized function as a cerebral inhibitory transmitter, less well established is the role of GABA in peripheral nervous and endocrine systems. We summarize current evidence that GABA serves as a neurotransmitter or neuromodulator in the autonomic nervous system and as a hormone or trophic factor in non-neuronal peripheral tissue as well. GABA is widely distributed in endocrine tissues including the pituitary, pancreas, adrenal glands, uterus, ovaries, placenta and testis. Moreover, GABA is involved in the pathophysiology of endocrine disorders such as diabetes mellitus, diseases of adrenal glands and reproductive tracts. Current literature indicates that the peripheral GABA system in the autonomic nervous system, endocrine and immune systems is as yet nearly an unexplored target for diagnosis and drug treatment.


Subject(s)
Endocrine System Diseases/physiopathology , gamma-Aminobutyric Acid/physiology , Adrenal Glands/physiology , Animals , Humans , Receptors, GABA/physiology , Reproduction/physiology
10.
Neuropharmacology ; 50(4): 428-40, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16309718

ABSTRACT

Affective disorders are common psychiatric illnesses characterized by marked gender-related prevalence. Recent evidence links chronic stress and dysregulation of neurotrophin signaling with the development of depression, while novel theories suggest that antidepressants may act by promoting intracellular adaptations linked to neuroplasticity. Although selective serotonin reuptake inhibitors (SSRIs) efficaciously improve a variety of dysfunctions in males, their neuroendocrine effects and intracellular signaling patterns in females are not well determined. Here we show that chronic footshock stress (21 days) promotes HPA axis hyperactivity (as seen by the increased FOS-ir in the paraventricular hypothalamic nucleus (PVN), plasma corticosterone and adrenal hypertrophy), reduces hippocampal BrdU immunoreactivity and suppresses cortical-limbic CREB phosphorylation in female rats. Long-term citalopram treatment, in contrast, attenuates stress-induced elevation of corticosterone levels and adrenal hypertrophy, although it does not reverse footshock-mediated induction of FOS-ir in the PVN, inhibition of CREB phosphorylation and reduction of hippocampal BrdU-labeling. Moreover, citalopram administration was also associated with significant hypophagic effects and inhibition of CREB phosphorylation. These data suggest that, in female rats, normalization of chronic stress-induced HPA axis abnormalities may represent an initial phase of citalopram-mediated therapeutic actions and despite this SSRI's apparent lack of effects on neuroplasticity, we cannot exclude the possibility that some neurochemical adaptations occur in a later stage which may require more than 3 weeks of treatment to manifest.


Subject(s)
CREB-Binding Protein/metabolism , Citalopram/therapeutic use , Proto-Oncogene Proteins c-fos/metabolism , Stress, Psychological/drug therapy , Stress, Psychological/physiopathology , Animals , Antidepressive Agents, Second-Generation/therapeutic use , Bromodeoxyuridine , CREB-Binding Protein/drug effects , Corticosterone/blood , Electroshock , Immunohistochemistry , Male , Proto-Oncogene Proteins c-fos/drug effects , Rats , Rats, Wistar , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL